epocrates logo
epocrates logo
epocrates logo
  • 0

Government Health Agency News

FDA

Amneal recalls sulfamethoxazole/trimethoprim 400 mg/80 mg tablets due to microbial contamination

June 6, 2025

card-image

Amneal Pharmaceutical LLC issued a voluntary nationwide recall of three lots of Sulfamethoxazole/Trimethoprim Tablets, USP, 400 mg/80 mg, due to microbial contamination. The affected tablets, distributed between December 4, 2024, and May 15, 2025, may exhibit black spots on the surface, which were identified in a product quality complaint. Lab analysis confirmed the presence of microbial contamination, potentially Aspergillus species, which poses a serious risk, particularly to immunocompromised patients.

The recall affects only the 400 mg/80 mg strength in 100- and 500-count bottles, specifically lots AM241019, AM241019A, and AM241020. No other strengths or lots are impacted. While no adverse events have been reported to date, FDA warns that oral ingestion of contaminated tablets could lead to life-threatening infections. HCPs are advised to check inventory and quarantine affected lots immediately.

Source:

(2025, June 4). FDA. Amneal Pharmaceutical LLC Issues a Nationwide Recall of Sulfamethoxazole / Trimethoprim Tablets, USP, 400 mg/80 mg Only, Due to Microbial Contamination [Company Announcement]. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/amneal-pharmaceutical-llc-issues-nationwide-recall-sulfamethoxazole-trimethoprim-tablets-usp-400

Trending icon

TRENDING THIS WEEK

EPOCRATES CME

View Catalog

view all CME activities
learn more about epocrates plus
Clinical FAQ icon

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & Feedback
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information